FDA clears LivaNova's new mitral annuloplasty ring

|About: LivaNova PLC (LIVN)|By:, SA News Editor

The FDA grants 510(k) clearance for LivaNova's (NASDAQ:LIVN) MEMO 4D semi-rigid mitral annuloplasty ring, in sizes from 24-44mm, for the treatment of mitral regurgitation.

The first implantation of the device has already taken place.

Subscribe for full text news in your inbox